Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01716975 · ClinicalTrials.gov registry record · Phase 3

Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy

A Phase 3 study of Schizophrenia and Impaired Cognition, sponsored by FORUM Pharmaceuticals.

Completed
Registry status
Phase 3
Development phase
767
Enrollment target
20
Study locations

NCT01716975 is a Phase 3 study of Schizophrenia and Impaired Cognition that has completed, run by FORUM Pharmaceuticals. The registered enrollment target is 767 participants, above the 217-participant average among 315 other Schizophrenia trials with a reported enrollment target (253% higher). The trial reports 20 study locations across 5 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01716975, a Phase 3 study of Schizophrenia and Impaired Cognition, has completed, sponsored by FORUM Pharmaceuticals.

COMPLETED
Registry status
Phase 3
Development phase
767 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to determine if EVP-6124 (an alpha-7 nAChR agonist) enhances the cognitive abilities of subjects with Schizophrenia who are also taking stable antipsychotic therapy.

Conditions Studied

Schizophrenia Impaired Cognition

Interventions

  • DRUG Placebo
  • DRUG EVP-6124

Study Locations (20)

California

  • - Cerritos
  • - Chino
  • - Costa Mesa
  • - Garden Grove
  • - Glendale
  • - Norwalk
  • - Oakland
  • - Oakland Park
  • - Oceanside
  • - Riverside
  • - San Diego
  • - San Gabriel
  • - Santa Ana
  • - Sherman Oaks

Florida

  • - Bradenton
  • - Miami
  • - Miami Springs

Arizona

  • - Phoenixville

Arkansas

  • - Little Rock

District of Columbia

  • - Washington D.C.

Trial Details

FieldValue
Enrollment Target 767 participants
Start Date 2012-10
Est. Completion 2016-02
Phase Phase 3

Sponsor

FORUM Pharmaceuticals

13 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01716975

The ClinicalTrials.gov registry entry for NCT01716975 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 767 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 217-participant average among 315 other Schizophrenia trials with a reported enrollment target (253% higher). The listed sponsor is FORUM Pharmaceuticals, which has 13 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Schizophrenia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT01716975 reports 20 study locations spanning 5 distinct geographic areas - top geographies include California, Florida, Arizona.

Frequently Asked Questions

What is clinical trial NCT01716975 about?

NCT01716975 is a clinical study titled "Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy". The purpose of this study is to determine if EVP-6124 (an alpha-7 nAChR agonist) enhances the cognitive abilities of subjects with Schizophrenia who are also taking stable antipsychotic therapy.

What is the current status of trial NCT01716975?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 767 participants. The study started on 2012-10. Estimated completion is 2016-02.

What conditions does trial NCT01716975 study?

This clinical trial studies the following conditions: Schizophrenia, Impaired Cognition.

What interventions are being tested in trial NCT01716975?

The interventions under investigation include: Placebo (DRUG), EVP-6124 (DRUG).

Who is sponsoring clinical trial NCT01716975?

This trial is sponsored by FORUM Pharmaceuticals, which has 13 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01716975 being conducted?

This trial has 20 study locations across Arizona, Arkansas, California, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Schizophrenia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Schizophrenia

All registered trials for this condition

Impaired Cognition

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.